Drugs / Recombinant Interleukin-2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03308786 | Apr 2019 → Aug 2020 | HIV infectious disease | Case Western Reserve University | Terminated | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00004978 | Mar 2000 → Nov 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Interleukin-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03308786 ↗ |
| Known as | rIL-2 | “Recombinant interleukin-2 (rIL-2) therapy used with combination anti-HIV medication of choice.” NCT00004978 ↗ |
| Modality | Protein / enzyme biologic | “rIL-2, a cytokine that increases the risk of some bacterial infections.” PMID 20812949 ↗ Aug 2010 |
| Route | Subcutaneous | “given twice daily subcutaneously” NCT00004978 ↗ |